Thursday, December 19, 2013 2:42:42 PM
The company clearly has had a difficult history, which is why I think many institutions want to see beyond the Phase I data to get on board. But difficult histories are not unique in biotech - if you look at the long term charts of many companies, you see a common pattern of steady decline for many years while trials are being run and regular capital raises dilute shareholders until the treatment is proven or disproven; if proven, then the pattern reverses.
All that matters now is the look forward, and for me, NWBO is worth the risk that the inflection point is not far away. If and when it happens, the institutions that have stayed away will come back big given the eventual market of all solid cancers, boosting the gains accordingly.
FEATURED Element79 Gold Corp Provides Update on Nevada Portfolio • Aug 23, 2024 8:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM